Albireo Pharma (FRA:BDQM) Debt-to-Asset : 0.00 (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Debt-to-Asset?

Albireo Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.00 Mil. Albireo Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.00 Mil. Albireo Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2022 was €324.43 Mil. Albireo Pharma's debt to asset for the quarter that ended in Sep. 2022 was 0.00.

Albireo Pharma Debt-to-Asset Historical Data

The historical data trend for Albireo Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Debt-to-Asset Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Asset

Get a 7-Day Free Trial

0.03

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.03	0.04	0.04	-

Competitive Comparison of Albireo Pharma's Debt-to-Asset

For the Biotechnology subindustry, Albireo Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Albireo Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Debt-to-Asset falls into.

Albireo Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Albireo Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	8.854)	/	267.315
	=	0.03

Albireo Pharma's Debt-to-Asset for the quarter that ended in Sep. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	324.434
	=	0.00

Albireo Pharma (FRA:BDQM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Albireo Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (FRA:BDQM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines